INTRODUCTIONNonischaemic dilated cardiomyopathy (DCM) is defined as left ventricular (LV) dilation and systolic dysfunction in the absence of coronary artery disease or abnormal loading conditions proportionate to the degree of LV impairment. As one of the leading causes of heart failure (HF), DCM (either ischaemic or nonischaemic) is the most frequent indication for ventricular assist device and/or cardiac transplantation. The major determinant of adverse outcomes in DCM is the extent of LV dilation and contractile impairment, while the key therapeutic goal was reversal of these abnormalities and LV reverse remodelling.Improving outcome of DCM remains a difficult goal to achieve. The treatment of HF due to DCM, other than standard pharmaceuticals and heart transplantation, is limited. To improve the prognosis and quality of life for HF patients, either due to ischaemic or nonischaemic causes, therapeutic strategies should alter the remodelling process, regenerate cardiomyocytes and repair myocardium. Heart has no intrinsic muscular regeneration capacity. To restore cardiac function and regenerate cardiomyocytes, regenerative medicine techniques are being increasingly investigated. As a potential therapeutic approach, cell‐based therapies have rapidly emerged. Different cell strains used include bone marrow mononuclear cells (BMMCs), G‐CSF‐stimulated autologous CD34+ peripheral blood stem cells (PBSC), embryonic stem cells (ESCs), skeletal
European Journal of Clinical Investigation – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud